Postmarketing migraine survey of frovatriptan: effectiveness and tolerability vs previous triptans,NSAIDs or a combination

Abstract

Objective:

Compare the effectiveness and tolerability of current therapy with frovatriptan 2.5-mg tablets (in 1–3 migraines) in patients with migraine previously using other triptans, analgesics/nonsteroidal anti-inflammatory drugs (NSAIDs), or triptans and NSAIDs (T+NSAIDs).